682 results on '"Kumada, Hiromitsu"'
Search Results
2. A new imaging classification for safer radial access visceral intervention of the liver and optimal case selection: A preliminary report
3. Long-term Favorable Efficacy of Regular and Repeated Hospitalizations with a Personalized Diet and Exercise Treatment for Steatotic Liver Disease
4. HBcrAg-based risk score performs better than the HBV DNA-based scores for HCC prediction in grey zone patients who are HBeAg-negative
5. Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial
6. A Phase 1b Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116
7. Clinical outcome after cessation of nucleos(t)ide analog treatment in chronic hepatitis B patients who achieved HBsAg seroclearance
8. Two Cases of Advanced Hepatocellular Carcinoma Who Responded Well to the Combination of Durvalumab Plus Tremelimumab After Disease Progression During Atezolizumab Plus Bevacizumab Therapy Under Bevacizumab Withdrawal
9. Impact of genetic polymorphism to personalized diet and exercise program for steatotic liver disease
10. Impact of fibrosis on liver‐related event incidence in nonalcoholic fatty liver disease: A multicenter observational study
11. Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma
12. HBcrAg-based risk score predicts HCC better than HBV DNA-based risk scores in HBeAg-negative grey zone patients
13. Supplementary Figure 1 from Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
14. Data from Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma
15. Data from Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma
16. Supplementary Information from Integrative Transcriptome Analysis Reveals Common Molecular Subclasses of Human Hepatocellular Carcinoma
17. Treatment efficacy of diet and exercise program for fatty liver and pretreatment predictors
18. Health-related quality of life (HRQoL) impact of lenvatinib (len) plus pembrolizumab (pembro) versus len plus placebo (pbo) as first-line (1L) therapy for advanced hepatocellular carcinoma (aHCC): Phase 3 LEAP-002 study.
19. Usefulness of diet and exercise program for fatty liver-Trial of "Hospitalization program for improvement purpose for the fatty liver"
20. Favorable Impact of Serum TERT C228T for Prognosis after Surgical Resection for Liver Cancer
21. Well-preserved liver function enhances the clinical impact of curative-intent subsequent treatment during lenvatinib treatment for unresectable hepatocellular carcinoma
22. Simple Predictive Markers and Clinicopathological Features of Primary Liver Cancer following HCV Clearance with Direct-Acting Antivirals
23. Safety analysis of glecaprevir/pibrentasvir in patients with markers of advanced liver disease in clinical and real‐world cohorts
24. Clinicopathological assessment of steatohepatitic hepatocellular carcinoma
25. Phase IIa, randomised, double-blind study of GSK3389404 in patients with chronic hepatitis B on stable nucleos(t)ide therapy
26. The Impact of Lenvatinib on Tumor Blood Vessel Shrinkage of Hepatocellular Carcinoma during Treatment: An Imaging-Based Analysis
27. Sofosbuvir–velpatasvir in adults with hepatitis C virus infection and compensated cirrhosis in Japan
28. A case of drug-induced acute liver failure caused by corticosteroids
29. Impact of bodyweight‐based starting doses on the safety and efficacy of lenvatinib in primarily Japanese patients with hepatocellular carcinoma
30. A Post-marketing surveillance of ombitasvir/paritaprevir/ritonavir for patients with hepatitis C virus genotype 1b infection: A follow-up study of phase 2 and 3 clinical trials
31. Molecular signatures of long-term hepatocellular carcinoma risk in nonalcoholic fatty liver disease
32. Favorable impact of long‐term SGLT2 inhibitor for NAFLD complicated by diabetes mellitus: A 5‐year follow‐up study
33. Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease
34. The useful predictors of zinc deficiency for the management of chronic liver disease
35. Hepatitis B Core-Related Antigen Stratifies the Risk of Liver Cancer in HBeAg-Negative Patients With Indeterminate Phase
36. Changes in the Mean Intrahepatic Target Computed Tomography Attenuation Value During Treatment May be a Useful New Predictor of the Post-progression Survival Associated with Lenvatinib Treatment
37. Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma
38. Histological impact at 5 years after the start of sodium-glucose cotransporter 2 inhibitor for non-alcoholic steatohepatitis complicated by diabetes mellitus
39. Switching from entecavir to tenofovir disoproxil fumarate for HBeAg-positive chronic hepatitis B patients: a phase 4, prospective study
40. PNPLA3 genotype and fibrosis-4 index predict cardiovascular diseases of Japanese patients with histopathologically-confirmed NAFLD
41. Dynamics of Circulating miR-122 Predict Liver Cancer and Mortality in Japanese Patients with Histopathologically Confirmed NAFLD and Severe Fibrosis Stage
42. Renal safety and biochemical changes for two years of tenofovir alafenamide after switching from long‐term other nucleotide analogues treatment in patients with chronic hepatitis B
43. Effectiveness of tenofovir alafenamide for chronic hepatitis B patients with a poor response to the previously used nucleos(t)ide analogs
44. Comparison between Lumipulse Presto HBsAg-HQ and iTACT-HBsAgin Chronic Hepatitis B with Seroclearance of HBsAg by Architect HBsAg QT
45. Ultrasensitive Assay for Hepatitis B Core‐Related Antigen Predicts Hepatocellular Carcinoma Incidences During Entecavir
46. Efficacy and safety of apararenone (MT‐3995) in patients with nonalcoholic steatohepatitis: A randomized controlled study
47. A blood-based prognostic liver secretome signature and long-term hepatocellular carcinoma risk in advanced liver fibrosis
48. Two cases receiving retreatment with 12 weeks of glecaprevir and pibrentasvir for HCV genotype 2 infection who failed prior glecaprevir and pibrentasvir therapy
49. Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L + P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC).
50. Impact of bodyweight (BW)-based starting doses on safety and efficacy of lenvatinib (LEN) in patients (pts) with hepatocellular carcinoma (HCC).
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.